Nanocarrier-based delivery of arsenic trioxide for hepatocellular carcinoma therapy.
Nanomedicine (Lond)
; 17(26): 2037-2054, 2022 11.
Article
em En
| MEDLINE
| ID: mdl-36789952
Hepatocellular carcinoma (HCC) is the leading cause of cancer-related death worldwide; it is highly aggressive, has a poor prognosis and is often diagnosed late in the disease course. Arsenic trioxide (ATO), an established agent for the treatment of acute promyelocytic leukemia, has shown powerful therapeutic potential in the treatment of HCC. However, its narrow therapeutic window and severe toxicity, as well as resistance to ATO, limit its application for HCC treatment. Nanocarriers have been employed to deliver ATO to achieve effective therapeutic outcomes in HCC. This review describes the application of various nanocarrier-based delivery systems for ATO to enhance the effectiveness of tumor therapy and reduce its side effects, thus making it a promising therapeutic strategy for in HCC.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Arsenicais
/
Carcinoma Hepatocelular
/
Neoplasias Hepáticas
/
Antineoplásicos
Limite:
Humans
Idioma:
En
Revista:
Nanomedicine (Lond)
Ano de publicação:
2022
Tipo de documento:
Article
País de afiliação:
China